While SARRP is often used to investigate the effect of radiation therapy in preclinical oncology settings, it should be noted that the impact of radiation on normal tissues requires understanding and further research to mitigate both early and late effects. The use of...
Xstrahl in Action Researchers developed guidance on how and what to report in regard to dosimetry in radiation research.Publication Minimum reporting standards should be expected for preclinical radiobiology irradiators and dosimetryAuthors François Trompier, Larry A....
Xstrahl in Action A recent study aimed to characterize a detection system based on inorganic scintillators and determine its suitability for dosimetry in preclinical radiation research, using our Small Animal Radiation Research Platform (SARRP).Publication...
Xstrahl in Action Pelvic radiotherapy (RT) can cause debilitating bladder toxicities. In the recent study, researchers sought methods to protect against and alleviate RT-induced late bladder injury.Publication Prevention of radiation-induced bladder injury: A murine...
Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
David Fernandez-Antoran PhD, Group Leader, The Gurdon Institute, University of Cambridge, Cambridge, UKARAID Researcher, Head of Cell Competition and Radiation Biology Laboratory, IIS-Aragon, Zaragoza, Spain Ionising radiation is one of the most common environmental...
Xstrahl & SmART Scientific Solutions to showcase two new software solutions for radiation research at ICRR in Montréal, Canada
Xstrahl will demonstrate SmART-RAD and SmART-Contour at the 17th International Congress for Radiation Research (ICRR) August 27-30
Researchers sought to understand the role of kV treatment in locally advanced and/or metastatic breast cancer in which kV radiotherapy was used as the primary modality or as supportive treatment to linac-based RT to gain local tumor control and improve the patient’s quality of life. See details of the recent study, Kilovoltage radiotherapy as a supportive treatment in locally advanced or metastatic breast cancer – a series of six case reports, and the full report on six cases.
Contact Us